Report cover image

Connected Drug Delivery Devices Market (3rd Edition): Distribution by Type of Device, Mode of Connectivity, Route of Administration, Therapeutic Area & Geographical Regions – Trends and Forecast Till 2035

Publisher Roots Analysis
Published Feb 18, 2026
Length 500 Pages
SKU # ROAL20921833

Description

Connected Drug Delivery Devices Market: Overview

As per Roots Analysis, the global connected drug delivery market is estimated to grow from USD 5.3 billion in the current year to USD 12.7 billion by 2035, at a CAGR of 10.2% during the forecast period, till 2035.

Connected Drug Delivery Devices Market: Growth and Trends

Over the years, poor compliance to prescribed medications continues to be a significant issue in the healthcare field, leading to disease progression, increased hospitalization rates, mortality, and rising healthcare expenses. Studies indicate that approximately 66% of individuals in the United States receive at least one prescription, yet nearly 50% fail to adhere to their physicians' instructions for medication use. This challenge of non-adherence arises from multiple factors, such as complicated dosing regimens, restricted access to medications, and inadequate patient assistance. To address this, healthcare professionals and technology providers are using various strategies to streamline dosage plans, provide individualized medication schedules, and improve patient education.

Connected drug delivery devices represent a viable solution as these devices integrate traditional delivery methods with digital health technologies to improve adherence. These devices come with advanced features, sensors, and wireless connectivity that allow for smooth integration with mobile apps, digital health platforms, and electronic health records. Additionally, the linked drug delivery system allows for real-time tracking of medication consumption and patient health conditions, thus facilitating prompt clinical interventions and customized therapy modifications. By enhancing patient involvement and adherence, these devices not only bolster patient results but also help in reducing total healthcare costs.

Further, the integration of sensor technologies has transformed the capabilities of conventional drug delivery systems, allowing them to evolve into intelligent, interconnected solutions. Ongoing advancements in telehealth integration and broader acceptance of digital health tools are anticipated to fuel consistent growth in the connected drug delivery device market in the upcoming years.

Growth Drivers: Strategic Enablers of Market Expansion

Rising chronic disease prevalence, including diabetes, asthma, chronic obstructive pulmonary disease (COPD), and autoimmune disorders, fuels demand. This is due to the fact that connected drug delivery devices enable precise dosing and long-term therapy management. Technological advances in sensors, Bluetooth Low Energy, AI analytics, and IoT integration allow remote monitoring, data sharing with providers, and personalized interventions, boosting adherence and outcomes. Patient engagement and aging populations further accelerate growth, with market projections showing a higher CAGR driven by telehealth synergies and precision medicine shifts.

Market Challenges: Critical Barriers Impeding Progress

Connected drug delivery devices, which integrate sensors and apps for real-time adherence tracking and remote monitoring in chronic conditions like diabetes and asthma, face multifaceted market challenges that hinder their widespread adoption. High development and manufacturing costs driven by advanced sensors, R&D, precision assembly, and supply chain issues elevate prices above traditional devices, compounded by ongoing cloud fees, tariffs, and payer reimbursement gaps. Further, stringent regulatory hurdles for drug-device combinations and global compliance delays, clash with rapid tech evolution and limit AI innovations. In addition, cybersecurity and data privacy risks hamper user trust and restrict data sharing, while usage barriers like usability issues persist.

Connected Drug Delivery Devices Market: Key Insights

The report delves into the current state of the connected drug delivery devices market and identifies potential growth opportunities within industry. Some key findings from the report include:
  • The current market landscape features the presence of more than 80 manufacturers that offer various connected drug delivery devices; of these, majority are headquartered in North America.
  • Nearly 75% of the connected / smart drug delivery devices are currently commercially available; notably, most of these devices are intended for the administration of medications via subcutaneous route.
  • At present, over 30 innovative add-on sensors are available / under development for integration with conventional drug delivery devices; numerous add-on sensor manufacturers are start-ups based in Europe.
  • More than 55% of the add-on sensors are designed for drug delivery via inhalation; of these, over 85% of the sensors can support Bluetooth connectivity.
  • The majority of clinical trials registered in this domain till date have evaluated the safety and efficacy of various connected drug delivery devices; most of these studies have been conducted across multiple sites in the US.
  • The growing interest of stakeholders in this market is reflected from the rising partnerships established among various stakeholders in the recent past; in fact, close to 70% of the deals were inked in the last three years.
  • Investors are increasingly channelizing capital into connected drug delivery devices market for the development of advanced devices which are accelerating industry advancements.
  • The development process of a connected / smart drug delivery device involves various steps, ranging from planning, designing, engineering, process validation, manufacturing and assembly to commercialization.
  • The pioneer-migrator-settler map in blue ocean strategy analysis suggests that several connected drug delivery devices manufacturers focused on enhancing their products are likely to emerge as pioneers in the coming years.
  • Owing to the ability of connected drug delivery devices to provide precise dosing and remote patient monitoring, the market is anticipated to witness a notable growth (CAGR of 10.2%) over the next decade.
  • The connected drug delivery devices market in North America is expected to capture maximum share by 2035; further, majority of the devices manufactured for drug delivery are intended for metabolic disorders.
  • Driven by the growing adoption of smart and connected drug delivery solutions in the US, the connected drug delivery devices market is poised to grow at a higher CAGR over the forecast period.
  • Given the surge in demand for advanced drug delivery devices and the rising prevalence of chronic diseases, the connected drug delivery devices market is anticipated to rise steadily.
Connected Drug Delivery Devices Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Device
  • Connected / Smart Wearable Injectors
  • Connected / Smart Inhalers
  • Connected / Smart Pen Injectors
  • Connected / Smart Autoinjectors
  • Connected / Smart Needle-free Injection Systems
By Mode of Connectivity
  • Bluetooth-enabled Devices
  • Near Field Communication-enabled Devices
  • Cellular-enabled Devices
  • Wide Area Network-enabled Devices
By Route of Administration
  • Parenteral
  • Inhalational
By Therapeutic Area
  • Metabolic Disorders
  • Respiratory Disorders
  • Autoimmune Disorders
  • Other Disorders
By Geographical Regions
  • North America
  • US
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Japan
  • Rest of Asia-Pacific
Connected Drug Delivery Devices Market: Key Segments

Connected / Smart Wearable Injectors Account for the Largest Market Share

In the current year, the connected / smart wearable injectors holds the largest market share, and this trend is expected to persist in the coming years. This is due to the increasing prevalence of chronic diseases and the ongoing initiatives of stakeholders to incorporate enhanced features into their connected drug delivery devices. These improvements enhance monitoring, strengthen patient compliance, and allow data exchange with healthcare professionals.

Bluetooth-Enabled Connected / Smart Devices Hold the Highest Share in the Future

At present, Bluetooth-enabled connected / smart devices are expected to capture a larger share of the connected drug delivery devices market. Moreover, this segment is expected to experience substantial growth during the forecasted period. This is because Bluetooth connectivity is simple to set up, widely accessible on all smartphones, and operates without requiring any additional devices.

Parenteral Segment Holds the Highest Connected Drug Delivery Devices Market Share in the Current Year

According to our estimates, in the current year, the parenteral segment is likely to hold a larger market share. This is because it is the favored route for administering biologics and high-value treatments for chronic conditions. Further, the inhalation segment is expected to experience a higher CAGR over the forecast period, owing to the ease, versatility, and painless nature of drug delivery through this method, along with its ability for prolonged localized therapeutic effect.

North America Dominates the Market by Securing Highest Share

According to our estimates, North America is expected to dominate the connected drug delivery devices market share this year. Further, the Asia-Pacific market is expected to expand at a comparatively higher rate till 2035. The growth is driven by a rising number of biopharmaceutical start-ups, significant research and development efforts for innovative drug delivery systems, and an increase in device approvals for various disease therapies in this area.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:
  • Senior Director, Global Strategic Marketing, Medical, Large Company, US
  • Co-Founder and Chief Executive Officer, Small Company, US
  • Chief Executive Officer, Small Company, US
  • Chief Executive Officer and President, Mid-sized Company, US
  • Chief Executive Officer, Small Company, Italy
  • Vice President and Chief Scientist, Large Company, Israel
  • Director of Global Communications, and Former Vice President of Strategic Partnerships and Business Development, Mid-sized Company, US
  • Former Chief Executive Officer, Small Company, US
  • Former Director of Front-end Innovation and Head of Connected Health, Large Company, US
  • Former Vice President, Marketing and Alliance Management, Mid-sized Company, US
  • Advisor of Strategy and Business Development, Small Company, US
Example Players in Connected Drug Delivery Devices Market
  • Bigfoot Biomedical
  • BIOCORP
  • Eitan Medical
  • E3D Elcam Drug Delivery Device 
  • EoFlow
  • Gerresheimer
  • Insulet
  • Medtronic
  • Medtrum
  • Nemera
  • Phillips-Medisize 
  • Roche
  • Sonceboz
  • SOOIL Development
  • Tandem Diabetes Care
  • West Pharmaceutical Services
  • Ypsomed
Connected Drug Delivery Devices Market: Research Coverage
  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the connected drug delivery devices market, focusing on key market segments, including [A] type of device [B] mode of connectivity, [C] route of administration, [D] therapeutic area, and [E] geographical regions.
  • Connected / Smart Drug Delivery Devices Market Landscape: A detailed overview of the overall market landscape of integrated connected drug delivery devices, along with information on several relevant parameters, such as [A] stage of development, [B] launch year of device, [C] type of integrated device, [D] route of administration, [E] target indication, therapeutic area, [F] key features, [G] mode of connectivity, [H] availability of companion mobile application and availability of data storage / cloud platform, [I] year of establishment, [J] company size, [K] location of headquarters and [H] most active players.
  • Add-On Sensors Market Landscape: : A detailed overview overall market landscape of add-on sensors market landscape, along with information on several relevant parameters, such as [A] stage of development, [B] launch year of device, [C] compatible device, [D] route of administration, [E] target indication, [F] therapeutic area, [G] target indication, [H] key features, [I] mode of connectivity, [J] availability of companion mobile application and [K] availability of data storage / cloud platform, [L] year of establishment, [M] company size, [N] location of headquarters and [O] most active players.
  • Product Competitiveness Analysis: An insightful analysis of connected drug delivery devices and add-on sensors based on the [A] manufacturer strength and [B] portfolio strength.
  • Company Profiles: In-depth profiles of leading players manufacturing connected drug delivery devices in North America, Europe and Asia-Pacific based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
  • Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to connected drug delivery devices, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial status, [D] type of sponsor / collaborator, [E] study design [F] and geography.
  • Partnerships and Collaborations: An analysis of partnerships and collaborations inked between stakeholders, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] class of device, [D] type of integrated device, [E] most active players.
  • Funding and Investment Analysis: An analysis of funding and investment signed in the domain based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, [D] geography, [E] and most active players.
  • Value Chain Analysis: An in-depth value chain analysis featuring a discussion on various steps involved in the development of connected / smart drug delivery devices, including research and development (R&D), product manufacturing and assembly, product distribution, marketing and sales, and post-market surveillance, along with the information on cost requirements across each of the aforementioned stages.
  • Regulatory Landscape: An informative summary of various guidelines established and issued by major regulatory bodies for the approval of connected drug delivery devices, across different countries / geographical regions.
  • Case Studies: Detailed case studies on two most common indications (namely asthma and diabetes), featuring a brief description of the disease, its epidemiology, economic burden (imposed due to non-adherence to prescribed treatments), and a summary of the evolution of drug delivery devices and other strategies focused on improving therapy adherence among patients suffering from the indication.
  • Blue Ocean Analysis: A detailed analysis of the current and future market based on blue ocean strategy, covering a strategic plan / guide for emerging connected drug delivery device companies to help unlock an uncontested market, featuring strategic tools that can help them to shift towards a blue ocean in order to gain a competitive edge in the market.
  • SWOT Analysis: A detailed discussion on industry affiliated trends, opportunities and challenges, under a SWOT analysis, which are likely to impact the evolution of connected drug delivery devices market.
Key Questions Answered in this Report
  • Which are the leading companies in connected drug delivery devices market?
  • Which region dominates the connected drug delivery devices market?
  • What are the key trends observed in the connected drug delivery devices market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by connected drug delivery device developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.
  • Complementary PPT Insights Pack
  • Detailed Report Walkthrough Session with Research Team

Table of Contents

500 Pages
1. Preface
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. Research Methodology
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape And Market Trends
2.2.2. Market Forecast And Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences And Seminars
2.4.1.9. Government Portals
2.4.1.10. Media And Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases And Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types Of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages Of Primary Research
2.4.2.3. Techniques For Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered In Primary Research
2.4.2.4.1. Company Executives (Cxos)
2.4.2.4.2. Board Of Directors
2.4.2.4.3. Company Presidents And Vice Presidents
2.4.2.4.4. Research And Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors And Other Healthcare Providers
2.4.2.5. Ethics And Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools And Databases
2.5. Robust Quality Control
3. Market Dynamics
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (Tam)
3.3.2. Serviceable Addressable Market (Sam)
3.3.3. Serviceable Obtainable Market (Som)
3.3.4. Currently Acquired Market (Cam)
3.4. Forecasting Tools And Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. Macro-economic Indicators
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current And Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting The Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact Of Currency Fluctuations On The Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact Of Foreign Exchange Rate Volatility On The Market
4.2.3.2. Strategies For Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment Of Current Economic Conditions And Potential Impact On The Market
4.2.4.2. Historical Analysis Of Past Recessions And Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
4.2.5.2. Potential Impact Of Inflation On Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates And Their Impact On The Market
4.2.6.2. Strategies For Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type Of Commodity
4.2.7.2. Origins And Destinations
4.2.7.3. Values And Weights
4.2.7.4. Modes Of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies For Mitigating The Risks Associated With Trade Barriers
4.2.8.5. Impact Of Trade Barriers On The Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-ukraine War
4.2.9.2. Israel-hamas War
4.2.10. Covid Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response And Stimulus Measures
4.2.10.4. Future Outlook And Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. Executive Summary
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast And Opportunity Analysis
6. Introduction
6.1. Chapter Overview
6.2. Concept Of Microbiota And Microbiome
6.2.1. Discovery Of Human Microbiome
6.2.2. Functions Of Human Microbiome
6.3. Overview Of Gut Flora
6.3.1. Role Of Gut Flora In Human Health
6.3.2. Factors Affecting Gut Flora
6.3.2.1. Antibiotic Consumption
6.3.2.2. Age And Pregnancy
6.3.2.2.1. Mode Of Childbirth
6.3.2.2.2. Type Of Feeding
6.3.2.2.3. Antibiotic Consumption By Mother
6.3.2.3. Stress-related Factors
6.3.2.4. Dietary Factors
6.3.2.5. Impact Of Lifestyle
6.4. Microbiome And Associated Diseases
6.4.1. Cancer
6.4.2. Inflammatory Bowel Disease (Ibd)
6.4.3. Obesity
6.4.4. Parkinson’s Disease
6.4.5. Type 2 Diabetes
6.4.6. Other Disease Indications
6.5. Impact Of Microbiota On Drug Pharmacokinetics
6.6. Impact Of Microbiota On Therapeutic Outcomes
6.7. Microbiome Therapeutics
6.7.1. Probiotics
6.7.1.1. Beneficial Bacterial Strains
6.7.1.1.1. Lactobacilli
6.7.1.1.2. Bifidobacteria
6.7.1.1.3. Others
6.7.1.2. Key Therapeutic Areas
6.7.1.2.1. Antibiotic-associated Diarrhea (Aad)
6.7.1.2.2. Bacterial Vaginosis
6.7.1.2.3. High Blood Pressure
6.7.1.2.4. Hypercholesterolemia
6.7.1.2.5. Infectious Childhood Diarrhea (Icd)
6.7.1.2.6. Inflammatory Bowel Disease (Ibd)
6.7.1.2.7. Lactose Intolerance
6.7.1.2.8. Vitamin Production
6.7.1.2.9. Weight Management
6.7.1.3. Side Effects Of Probiotics
6.7.2. Prebiotics
6.7.2.1. Sources Of Prebiotics
6.7.2.2. Types Of Prebiotics
6.7.2.2.1. Fructo-oligosaccharides (Fos)
6.7.2.2.2. Galacto-oligosaccharides (Gos)
6.7.2.2.3. Inulin
6.7.2.3. Key Therapeutic Areas
6.7.2.3.1. Antibiotic Associated Diarrhea (Aad)
6.7.2.3.2. Constipation
6.7.2.3.3. Gastrointestinal Diseases
6.7.2.3.4. Dysbiosis
6.7.2.4. Side Effects Of Prebiotics
6.8. The Human Microbiome Project (Hmp)
6.8.1. Project Approach
6.8.2. Project Initiatives
6.8.3. Project Achievements
6.9. Regulatory Guidelines For Live Biotherapeutic Products (Lbps)
6.10. Key Challenges Associated With The Development Of Microbiome Therapeutics
6.11. Future Perspectives
7. Human Microbiome Therapeutics: Market Landscape
7.1. Chapter Overview
7.2. Human Microbiome Therapeutics: Overall Market Landscape
7.2.1. Analysis By Stage Of Development
7.2.2. Analysis By Type Of Molecule
7.2.3. Analysis By Stage Of Development And Type Of Molecule
7.2.4. Analysis By Type Of Biologic
7.2.5. Analysis By Target Indication
7.2.6. Analysis By Therapeutic Area
7.2.7. Analysis By Route Of Administration
7.2.8. Analysis By Type Of Formulation
7.2.9. Analysis By Dosage Frequency
7.2.10. Analysis By Type Of Therapy
7.3. Human Microbiome Therapeutics: Developer Landscape
7.3.1. Analysis By Year Of Establishment
7.3.2. Analysis By Company Size
7.3.3. Analysis By Location Of Headquarters (Region)
7.3.4. Analysis By Location Of Headquarters (Country)
7.3.5. Most Active Players: Analysis By Number Of Microbiome Therapeutics
8. Human Microbiome Diagnostics And Screening / Profiling Tests: Market Landscape
8.1. Chapter Overview
8.2. Overview Of Microbiome Diagnostics And Screening / Profiling Tests
8.3. Microbiome Diagnostics And Screening / Profiling Tests: Overall Market Landscape
8.3.1. Analysis By Stage Of Development
8.3.2. Analysis By Type Of Sample Analyzed
8.3.3. Analysis By Type Of Screening Technique
8.3.4. Analysis By Target Indication
8.3.5. Analysis By Therapeutic Area
8.3.6. Analysis By Purpose Of Test
8.4. Microbiome Diagnostic And Screening / Profiling Tests: Provider Landscape
8.4.1. Analysis By Year Of Establishment
8.4.2. Analysis By Company Size
8.4.3. Analysis By Location Of Headquarters (Region)
8.4.4. Analysis By Location Of Headquarters (Country)
8.4.5. Most Active Players: Analysis By Number Of Microbiome Tests
9. Human Microbiome Fecal Microbota Therapies: Market Landscape
9.1. Chapter Overview
9.2. Introduction To Fecal Microbiota Therapies (Fmt)
9.3. Historical Overview
9.4. Fecal Microbiota Therapies: Procedure And Clinical Relevance
9.4.1. Donor Selection
9.4.2. Administration Procedure
9.4.3. Routes Of Administration
9.4.4. Consequences And Adverse Events
9.4.5. Clinical Guidelines Associated With Fmt
9.5. Regulatory Guidelines Related To Fecal Microbiota Therapies
9.6. Insurance Coverage For Fecal Microbiota Therapies
9.7. Fecal Microbiota Therapies: Overall Market Landscape
9.7.1. Marketed / Development Pipeline
9.7.1.1. Analysis By Application Area
9.7.1.2. Analysis By Status Of Development
9.7.1.3. Analysis By Target Indication
9.7.1.4. Analysis By Therapeutic Area
9.7.1.5. Analysis By Route Of Administration
9.7.2. Fecal Microbiota Therapies: Developer Landscape
9.7.2.1. Analysis By Year Of Establishment
9.7.2.2. Analysis By Company Size
9.7.2.3. Analysis By Location Of Headquarters (Region)
9.7.2.4. Analysis By Location Of Headquarters (Country)
10. Human Microbiome Therapeutics: Company And Drug Profiles
10.1. Chapter Overview
10.2. Ferring Pharmaceuticals
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Microbiome-based Product Portfolio
10.2.3.1. Rebyota
10.2.3.1.1. Drug Overview
10.2.3.1.2. Current Status Of Development
10.2.3.1.3. Clinical Studies
10.2.4. Recent Developments And Future Outlook
10.3. Infant Bacterial Therapeutics
10.4. Maat Pharma
10.5. Mikrobiomik
10.6. Seres Therapeutics
10.7. Oxthera
10.8. Vedanta Biosciences
10.9. Zhiyi Biotech
11. Microbiome Diagnostic And Screening / Profiling Test Providers: Company Profiles
11.1. Chapter Overview
11.2. Becton, Dickinson And Company
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Microbiome Diagnostic Test Portfolio
11.2.4. Recent Developments And Future Outlook
11.3. Biome Diagnostics
11.4. Goodgut
11.5. Nutripath
11.6. Tiny Health
12. Clinical Trial Analysis
12.1. Chapter Overview
12.2. Scope And Methodology
12.3. Fecal Microbiota Therapies: Clinical Trial Analysis
12.3.1. Analysis By Trial Registration Year
12.3.2. Analysis Of Enrolled Patient Population By Trial Registration Year
12.3.3. Analysis By Trial Status
12.3.4. Analysis Of Enrolled Patient Population By Trial Status
12.3.5. Analysis By Trial Registration Year And Trial Status
12.3.6. Analysis By Trial Phase
12.3.7. Analysis Of Enrolled Patient Population By Trial Phase
12.3.8. Analysis By Type Of Sponsor / Collaborator
12.3.9. Analysis By Study Design
12.3.10. Analysis By Gender
12.3.11. Leading Industry Players: Analysis By Number Of Registered Trials
12.3.12. Leading Non-industry Players: Analysis By Number Of Registered Trials
12.3.13. Analysis By Trial Status, Trial Phase And Geography
12.3.14. Analysis By Geography
12.3.15. Analysis By Trial Status And Geography
12.3.16. Analysis Of Enrolled Patient Population By Trial Status And Geography
13. Attractiveness Competitiveness (Ac) Matrix
13.1. Chapter Overview
13.2. Ac Matrix: An Overview
13.2.1. Strong Business Units
13.2.2. Average Business Units
13.2.3. Weak Business Units
13.3. Ac Matrix: Analytical Methodology
13.4. Ac Matrix: Plotting The Information
13.5. Ac Matrix: Analyzing The Data
13.5.1. Strong Business Units
13.5.2. Average Business Units
13.5.3. Weak Business Units
13.6. Concluding Remarks
14. Start-up Health Indexing
14.1. Chapter Overview
14.2. Scope And Methodology
14.3. Benchmarking Of Start-ups
14.3.1. Analysis By Portfolio Strength
14.3.2. Analysis By Pipeline Maturity
14.3.3. Analysis By Indication Diversity
14.3.4. Analysis By Funding Amount
14.3.5. Analysis By Partnership Activity
14.3.6. Start-up Health Indexing: Roots Analysis Perspective
14.3.7. Start-up Health Indexing: Leading Companies
15. Case Study: Key Therapeutic Areas
15.1. Chapter Overview
15.2. Metabolic Disorders
15.2.1. Diabetes
15.2.1.1. Disease Description
15.2.1.2. Associated Health Risks / Complications
15.2.1.3. Epidemiology
15.2.1.4. Disease Diagnosis
15.2.1.5. Current Treatment Options
15.2.1.5.1. Insulin Therapies
15.2.1.5.2. Non-insulin Therapies
15.2.1.6. Side Effects Of Current Treatment Options
15.2.1.7. Microbiome Therapeutics For Diabetes
15.2.2. Lactose Intolerance
15.2.2.1. Disease Description
15.2.2.2. Epidemiology
15.2.2.3. Current Treatment Options
15.2.2.4. Microbiome Therapeutics For Lactose Intolerance
15.2.3. Nonalcoholic Steatohepatitis (Nash)
15.2.3.1. Disease Description
15.2.3.2. Epidemiology
15.2.3.3. Current Treatment Options
15.2.3.4. Microbiome Therapeutics For Nash
15.2.4. Primary Hyperoxaluria
15.2.4.1. Disease Description
15.2.4.2. Epidemiology
15.2.4.3. Current Treatment Options
15.2.4.4. Microbiome Therapeutics For Primary Hyperoxaluria
15.2.5. Obesity
15.2.5.1. Disease Description
15.2.5.2. Epidemiology
15.2.5.3. Current Treatment Options
15.2.5.4. Side Effects Of Current Treatment Options
15.2.5.5. Microbiome Therapeutics For Obesity
15.3. Digestive And Gastrointestinal Disorders
15.3.1. Crohn’s Disease
15.3.1.1. Disease Description
15.3.1.2. Epidemiology
15.3.1.3. Current Treatment Options
15.3.1.4. Side Effects Of Current Treatment Options
15.3.1.5. Microbiome Therapeutics For Crohn’s Disease
15.3.2. Irritable Bowel Syndrome (Ibs)
15.3.2.1. Disease Description
15.3.2.2. Epidemiology
15.3.2.3. Current Treatment Options
15.3.2.4. Microbiome Therapeutics For Ibs
15.3.3. Ulcerative Colitis
15.3.3.1. Disease Description
15.3.3.2. Epidemiology
15.3.3.3. Current Treatment Options
15.3.3.4. Side Effects Of Current Treatment Options
15.3.3.5. Microbiome Therapeutics For Ulcerative Colitis
15.4. Oncological Indications
15.4.1. Colorectal Cancer
15.4.1.1. Disease Description
15.4.1.2. Epidemiology
15.4.1.3. Current Treatment Options
15.4.1.4. Side Effects Of Current Treatments
15.4.1.5. Microbiome Therapeutics For Colorectal Cancer
15.4.2. Lung Cancer
15.4.2.1. Disease Description
15.4.2.2. Epidemiology
15.4.2.3. Current Treatment Options
15.4.2.4. Side Effects Of Current Treatment Options
15.4.2.5. Microbiome Therapeutics For Lung Cancer
15.5. Dermatological Disorders
15.5.1. Acne Vulgaris
15.5.1.1. Disease Description
15.5.1.2. Epidemiology
15.5.1.3. Current Treatment Options
15.5.1.4. Side Effects Of Current Treatment Options
15.5.1.5. Microbiome Therapeutics For Acne Vulgaris
15.6. Infectious Diseases
15.6.1. Clostridium Difficile Infections (Cdis)
15.6.1.1. Disease Description
15.6.1.2. Epidemiology
15.6.1.3. Disease Diagnosis
15.6.1.4. Current Treatment Options
15.6.1.5. Side Effects Of Current Treatment Options
15.6.1.6. Microbiome Therapeutics For Cdi
15.6.2. Bacterial Vaginosis
15.6.2.1. Disease Description
15.6.2.2. Epidemiology
15.6.2.3. Current Treatment Options
15.6.2.4. Side Effects Of Current Treatment Options
15.6.2.5. Microbiome Therapeutics For Bacterial Vaginosis
16. Partnerships And Collaborations
16.1. Chapter Overview
16.2. Partnership Models
16.3. Human Microbiome: List Of Partnerships And Collaborations
16.4. Analysis By Year Of Partnership
16.5. Analysis By Type Of Partnership
16.6. Analysis By Year And Type Of Partnership
16.7. Analysis By Target Indication
16.8. Analysis By Therapeutic Area
16.9. Analysis By Type Of Partnership And Therapeutic Area
16.10. Analysis By Type Of Partner
16.11. Most Active Players: Analysis By Number Of Partnerships
16.12. Analysis By Geography
16.12.1. Local And International Deals
16.12.2. Intracontinental And Intercontinental Deals
17. Funding And Investments
17.1. Chapter Overview
17.2. Funding Models
17.3. Human Microbiome: List Of Funding And Investments
17.3.1. Analysis Of Funding Instances By Year Of Funding
17.3.2. Analysis Of Amount Invested By Year Of Funding
17.3.3. Analysis By Type Of Funding
17.3.4. Analysis By Year And Type Of Funding
17.3.5. Analysis By Amount Invested And Type Of Funding
17.3.6. Analysis By Purpose Of Funding
17.3.7. Analysis By Target Indication
17.3.8. Analysis By Therapeutic Area
17.3.9. Analysis By Geography
17.3.10. Most Active Players: Analysis By Number Of Instances
17.3.11. Most Active Players: Analysis By Amount Invested
17.3.12. Leading Investors: Analysis By Number Of Instances
17.3.13. Funding And Investment Summary
18. Case Study: Contract Services For Microbiome Therapeutics And Live Biotherapeutics
18.1. Chapter Overview
18.2. Manufacturing Microbiome Therapeutics
18.2.1. Key Steps Involved
18.2.2. Associated Challenges
18.2.3. Growing Demand For Contract Manufacturing Services
18.2.4. Contract Manufacturing Organizations (Cmos)
18.2.4.1. Introduction To Contract Manufacturing
18.2.5. Microbiome Therapeutics: List Of Contract Manufacturing Providers
18.2.5.1. Analysis By Year Of Establishment
18.2.5.2. Analysis By Company Size
18.2.5.3. Analysis By Location Of Headquarters
18.2.5.4. Analysis By Scale Of Operation
18.2.5.5. Analysis By Type Of Product Manufactured
18.2.5.6. Analysis By Type Of Formulation
18.2.5.7. Analysis By Scale Of Operation And Type Of Formulation
18.3. Key Considerations For Selecting A Cmo / Cro Partner
19. Case Study: Big Data And Microbiome Therapeutics
19.1. Chapter Overview
19.2. Introduction To Big Data
19.3. Internet Of Things (Iot)
19.4. Growing Interest In Big Data: Google Trends Analysis
19.5. Key Application Areas
19.6. Big Data In Microbiome Research
19.6.1. Microbiome Data And Personalized Medicine
19.6.2. Microbiome-related Data Management Challenges
19.6.3. National Microbiome Data Center
19.7. Big Data Services For Microbiome Research: List Of Companies
19.8. Big Data Services For Microbiome Research: Profiles Of Key Players
19.8.1. Human Longevity
19.8.1.1. Company Overview
19.8.1.2. Technology And Service Portfolio
19.8.1.3. Recent Developments And Future Outlook
19.8.2. Resilient Biotics
19.8.2.1. Company Overview
19.8.2.2. Technology And Service Portfolio
19.8.2.3. Recent Developments And Future Outlook
19.8.3. Resphera Biosciences
19.8.3.1. Company Overview
19.8.3.2. Technology And Service Portfolio
19.8.3.3. Recent Developments And Future Outlook
20. Human Microbiome Therapeutics Market
20.1. Chapter Overview
20.2. Assumptions And Methodology
20.3. Global Human Microbiome Therapeutics Market: Forecasted Estimates (Till 2035)
20.4. Human Microbiome Market: Distribution By Type Of Product
20.4.1. Therapeutics: Forecasted Estimates (Till 2035)
20.4.2. Diagnostics: Forecasted Estimates (Till 2035)
20.4.3. Fecal Microbiota Therapies: Forecasted Estimates (Till 2035)
20.4.4. Scenario Analysis
20.4.4.1. Conservative Scenario
20.4.4.2. Optimistic Scenario
20.5. Key Market Segmentations
21. Human Microbiome Therapeutics Market, By Type Of Biologic
21.1. Chapter Overview
21.2. Assumptions And Methodology
21.3. Distribution By Type Of Biologic
21.3.1. Live Biotherapeutics: Forecasted Estimates (Till 2035)
21.3.2. Others: Forecasted Estimates (Till 2035)
21.4. Data Triangulation And Validation
22. Human Microbiome Therapeutics Market, By Route Of Administration
22.1. Chapter Overview
22.2. Key Assumptions And Methodology
22.3. Distribution By Route Of Administration
22.3.1. Oral Route: Forecasted Estimates (Till 2035)
22.3.2. Rectal Route: Forecasted Estimates (Till 2035)
22.4. Data Triangulation And Validation
23. Human Microbiome Therapeutics Market, By Drug Formulation
23.1. Chapter Overview
23.2. Key Assumptions And Methodology
23.3. Distribution By Drug Formulation
23.3.1. Capsules: Forecasted Estimates (Till 2035)
23.3.2. Suspensions: Forecasted Estimates (Till 2035)
23.3.3. Enemas: Forecasted Estimates (Till 2035)
23.3.4. Powders: Forecasted Estimates (Till 2035)
23.4. Data Triangulation And Validation
24. Human Microbiome Therapeutics Market, By Target Indication
24.1. Chapter Overview
24.2. Key Assumptions And Methodology
24.3. Distribution By Target Indication
24.3.1. Clostridium Difficile Infection
24.3.2. Necrotizing Enterocolitis
24.3.3. Irritable Bowel Syndrome
24.3.4. Acute Graft Versus Host Disease
24.4. Data Triangulation And Validation
25. Human Microbiome Therapeutics Market, By Target Therapeutic Area
25.1. Chapter Overview
25.2. Key Assumptions And Methodology
25.3. Distribution By Therapeutic Area
25.3.1. Infectious Diseases
25.3.2. Gastrointestinal Disorders
25.3.3. Rare Disorders
25.4. Data Triangulation And Validation
26. Human Microbiome Therapeutics Market, By Geographical Regions
26.1. Chapter Overview
26.2. Key Assumptions And Methodology
26.3. Distribution By Geographical Regions
26.3.1. North America
26.3.2. Europe
26.3.3. Asia-pacific
26.3.4. Latin America
26.3.5. Middle East And North Africa
26.4. Market Dynamics Assessment
26.4.1. Penetration Growth (P-g) Matrix
26.4.2. Market Movement Analysis
26.5. Data Triangulation And Validation
27. Human Microbiome Diagnostics Market
27.1. Chapter Overview
27.2. Assumptions And Methodology
27.3. Global Human Microbiome Diagnostics Market: Forecasted Estimates (Till 2035)
27.3.1. Scenario Analysis
27.4. Key Market Segmentations
28. Human Microbiome Diagnostics Market, By Target Indication
28.1. Chapter Overview
28.2. Key Assumptions And Methodology
28.3. Market Distribution By Target Indication
28.3.1. Diabetes Mellitus: Forecasted Estimates (Till 2035)
28.3.2. Irritable Bowel Syndrome: Forecasted Estimates (Till 2035)
28.3.3. Irritable Bowel Disease: Forecasted Estimates (Till 2035)
28.3.4. Colorectal Cancer: Forecasted Estimates (Till 2035)
28.4. Data Triangulation And Validation
29. Human Microbiome Diagnostics Market, By Target Therapeutic Area
29.1. Chapter Overview
29.2. Key Assumptions And Methodology
29.3. Market Distribution By Therapeutic Area
29.3.1. Gastrointestinal Disorders: Forecasted Estimates (Till 2035)
29.3.2. Metabolic Disorders: Forecasted Estimates (Till 2035)
29.3.3. Oncological Disorders: Forecasted Estimates (Till 2035)
29.4. Data Triangulation And Validation
30. Human Microbiome Diagnostics Market, By Geographical Regions
30.1. Chapter Overview
30.2. Key Assumptions And Methodology
30.3. Market Distribution By Geographical Regions
30.3.1. North America: Forecasted Estimates (Till 2035)
30.3.2. Europe: Forecasted Estimates (Till 2035)
30.3.3. Asia-pacific: Forecasted Estimates (Till 2035)
30.3.4. Latin America: Forecasted Estimates (Till 2035)
30.3.5. Middle East And North Africa: Forecasted Estimates (Till 2035)
30.4. Data Triangulation And Validation
30.5. Market Dynamics Assessment
30.5.1. Penetration Growth (P-g) Matrix
30.5.2. Market Movement Analysis
30.6. Data Triangulation And Validation
31. Human Microbiome Fecal Microbiota Therapies Market
31.1. Chapter Overview
31.2. Assumptions And Methodology
31.3. Global Market: Forecasted Estimates (Till 2035)
31.3.1. Scenario Analysis
31.3.1.1. Conservative Scenario
31.3.1.2. Optimistic Scenario
31.4. Key Market Segmentations
32. Human Microbiome Fecal Microbiota Therapies Market, By Geographic Regions
32.1. Chapter Overview
32.2. Key Assumptions And Methodology
32.3. Distribution By Geographic Regions
32.3.1. North America
32.3.2. Europe
32.3.3. Asia-pacific
32.3.4. Latin America
32.3.5. Middle East And North Africa
32.4. Data Triangulation And Validation
32.5. Market Dynamics Assessment
32.5.1. Penetration Growth (P-g) Matrix
32.5.2. Market Movement Analysis
32.6. Data Triangulation And Validation
33. Human Microbiome Therapeutics Market Opportunity Analysis: North America
33.1. Market Distribution By Type Of Biologic
33.2. Market Distribution By Route Of Administration
33.3. Market Distribution By Drug Formulation
33.4. Market Distribution By Target Indication
33.5. Market Distribution By Target Therapeutic Area
34. Human Microbiome Therapeutics Market Opportunity Analysis: Europe
34.1. Market Distribution By Type Of Biologic
34.2. Market Distribution By Route Of Administration
34.3. Market Distribution By Drug Formulation
34.4. Market Distribution By Target Indication
34.5. Market Distribution By Target Therapeutic Area
35. Human Microbiome Therapeutics Market Opportunity Analysis: Asia-pacific
35.1. Market Distribution By Type Of Biologic
35.2. Market Distribution By Route Of Administration
35.3. Market Distribution By Drug Formulation
35.4. Market Distribution By Target Indication
35.5. Market Distribution By Target Therapeutic Area
36. Human Microbiome Therapeutics Market Opportunity Analysis: Latin America
36.1. Market Distribution By Type Of Biologic
36.2. Market Distribution By Route Of Administration
36.3. Market Distribution By Drug Formulation
36.4. Market Distribution By Target Indication
36.5. Market Distribution By Target Therapeutic Area
37. Human Microbiome Therapeutics Market Opportunity Analysis: Middle East And North Africa
37.1. Market Distribution By Type Of Biologic
37.2. Market Distribution By Route Of Administration
37.3. Market Distribution By Drug Formulation
37.4. Market Distribution By Target Indication
37.5. Market Distribution By Target Therapeutic Area
38. Human Microbiome Diagnostics Market Opportunity Analysis: North America
38.1. Distribution By Target Indication
38.2. Distribution By Target Therapeutic Area
39. Human Microbiome Diagnostics Market Opportunity Analysis: Europe
39.1. Distribution By Target Indication
39.2. Distribution By Target Therapeutic Area
40. Human Microbiome Diagnostics Market Opportunity Analysis: Asia-pacific
40.1. Distribution By Target Indication
40.2. Distribution By Target Therapeutic Area
41. Human Microbiome Diagnostics Market Opportunity Analysis: Latin America
41.1. Distribution By Target Indication
41.2. Distribution By Target Therapeutic Area
42. Human Microbiome Diagnostics Market Opportunity Analysis: Middle East And North Africa
42.1. Distribution By Target Indication
42.2. Distribution By Target Therapeutic Area
43. Concluding Insights
44. Executive Insights
44.1. Chapter Overview
44.2. Company A (Mid-sized Company, Uk)
44.2.1. Company Snapshot
44.2.2. Interview Transcript: Former Senior Manager, Corporate Development
44.3. Company B (Small Company, Us)
44.3.1. Company Snapshot
44.3.2. Interview Transcript: Co-founder And Chairman
44.4. Company C (Small Company, Us)
44.4.1. Company Snapshot
44.4.2. Interview Transcript: Chief Executive Officer
44.5. Company D (Large Company, Us)
44.5.1. Company Snapshot
44.5.2. Interview Transcript: Senior Scientist
44.6. Company E (Small Company, Taiwan)
44.6.1. Company Snapshot
44.6.2. Interview Transcript: President
44.7. Company F (Small Company, Us)
44.7.1. Company Snapshot
44.7.2. Interview Transcript: Vice President, Business Development
44.8. Company G (Mid-sized Company, Israel)
44.8.1. Company Snapshot

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us